- Home
- BME vs LBRX Comparison
BME vs LBRX Comparison
Compare BME & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BME | LBRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.5M | 602.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | BME | LBRX |
|---|---|---|
| Price | $42.20 | $24.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | 33.2K | ★ 181.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $13.40 |
| 52 Week High | $42.63 | $25.60 |
Technical Indicators
Market Signals| Indicator | BME | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 56.55 |
| Support Level | $41.21 | $22.48 |
| Resistance Level | $42.46 | $24.70 |
| Average True Range (ATR) | 0.45 | 1.21 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 57.84 | 58.85 |
Price Performance
Historical ComparisonAbout BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.